3/3
09:15 am
pbm
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
Medium
Report
Psyence BioMed Announces Export of GMP-Manufactured Natural Psilocybin (NPX-5) to Australia for Ongoing Phase IIb Clinical Trial
2/20
05:20 pm
pbm
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
High
Report
Psyence BioMed Announces Exercise of Put Option by PsyLabs and Strategic Equity Investment
2/17
09:15 am
pbm
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
Medium
Report
Psyence BioMed Announces Results of Annual and Special Meeting of Shareholders
2/13
06:30 pm
pbm
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
High
Report
Psyence BioMed Approves Put Option Agreement with PsyLabs to Secure Strategic Supply and Strengthen Commercialization Pathway
2/11
09:15 am
pbm
Psyence BioMed Announces Settlement of Shareholder Litigation
Medium
Report
Psyence BioMed Announces Settlement of Shareholder Litigation
1/29
09:24 am
pbm
Court sides with psychedelic biotech, over hedge fund [Advisor.ca (Canada)]
Low
Report
Court sides with psychedelic biotech, over hedge fund [Advisor.ca (Canada)]
1/29
09:22 am
pbm
Court sides with psychedelic biotech, over hedge fund [Investment Executive - News]
Medium
Report
Court sides with psychedelic biotech, over hedge fund [Investment Executive - News]
1/28
06:30 pm
pbm
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Low
Report
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
1/22
01:42 pm
pbm
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
Low
Report
Psyence BioMed Announces Adjournment of Annual and Special Shareholder Meeting on January 22, 2026
1/20
07:19 am
pbm
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
Neutral
Report
Psyence BioMed Announces Postponement of Previously Announced Reverse Stock Split Effective Date
1/14
07:00 pm
pbm
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
Low
Report
Psyence BioMed Announces Effective Date for 1-for-6.25 Reverse Stock Split
1/12
08:30 am
pbm
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
Medium
Report
Psyence BioMed Approves 2026 Financial Strategy, Board Authorizes Share Buyback on Value Opportunity
1/5
11:28 am
pbm
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash [Canadian Business Journal (Canada)]
Medium
Report
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash [Canadian Business Journal (Canada)]
1/5
09:15 am
pbm
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
Medium
Report
Psyence BioMed Achieves Milestone in Natural Ibogaine HCl Production and Strengthens Balance Sheet With No Debt and $12m Cash
12/19
07:49 am
pbm
Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial [Yahoo! Finance]
High
Report
Psyence BioMed Announces Approval for Use of PsyLabs' Psilocybin Product in Phase IIb Clinical Trial [Yahoo! Finance]
12/19
07:28 am
pbm
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial [Canadian Business Journal (Canada)]
High
Report
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial [Canadian Business Journal (Canada)]
12/19
07:00 am
pbm
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
High
Report
Psyence BioMed Announces Approval for Use of PsyLabs’ Psilocybin Product in Phase IIb Clinical Trial
12/9
07:00 am
pbm
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science
Medium
Report
Psyence BioMed CEO Letter Highlights Clinical Progress, Ethical Sourcing of Ibogaine, Strong Cash Position and Expanding Leadership in Longevity Science